BioSpace News Archive

Sutro Biopharma, Inc. today announced that Merck has extended the research term for the first cytokine derivative program under the 2018 Merck Agreement, for an additional two years.

OncoNano Medicine to Present at The American Association for Cancer Research Virtual Conference on Tumor Immunology and Immunotherapy

Starton Therapeutics Inc. announces the results of a preclinical toxicology study for STAR-LLD. STAR-LLD is a continuous delivery system of lenalidomide in development for chronic lymphocytic leukemia and multiple myeloma.

Broncus Holding Corporation is pleased to announce that it has completed the first-in-man clinical trial of its Targeted Lung Denervation (TLD) radiofrequency ablation system, which is expected to benefit patients with chronic obstructive pulmonary disease (“COPD”) worldwide.

Edison Oncology Holding Corp. reported that the first patient was dosed with EO1001 (APL-122) in a Phase I/IIa clinical trial in patients with advanced solid tumors.

Revolution Medicines, Inc. today announced that new preclinical data from several of the company’s RAS(ON) inhibitor programs will be reported in an invited oral presentation during a plenary session of the upcoming AACR-NCI-EORTC Virtual International Conference being held on October 7-10, 2021.

OpGen, Inc. announced today that it has initiated the clinical trial for its Unyvero Urinary Tract Infection (UTI) Panel, which allows testing for a broad range of pathogens as well as antimicrobial resistance markers directly from native urine specimens.

Adaptive Biotechnologies Corporation announced today the launch of an enhanced version of its clonoSEQ ® B-cell Clonality (ID) report, which will now feature the immunoglobulin heavy chain (IgH) – V mutation status for patients with chronic lymphocytic leukemia (CLL).

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present interim data on Rhenium-186 NanoLiposome (186RNL) from its ReSPECT™ Phase 1 clinical trial in recurrent glioblastoma (GBM) at the 2021 Society for Neuro-Oncology (SNO) Annual Meeting and Education Day

Mersana Therapeutics, Inc. (NASDAQ:MRSN), today announced that it will disclose the target and present new preclinical data for XMT-2056, its first Immunosynthen STING-agonist ADC candidate, in a plenary session at the upcoming AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.